Literature DB >> 23679915

Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.

Ubaldina Galli1, Cristina Travelli, Alberto Massarotti, Gohar Fakhfouri, Reza Rahimian, Gian Cesare Tron, Armando A Genazzani.   

Abstract

Nicotinamide phoshophoribosyltransferase (NAMPT) plays a key role in the replenishment of the NAD pool in cells. This in turn makes this enzyme an important player in bioenergetics and in the regulation of NAD-using enzymes, such as PARPs and sirtuins. Furthermore, there is now ample evidence that NAMPT is secreted and has a role as a cytokine. An important role of either the intracellular or extracellular form of NAMPT has been shown in cancer, inflammation, and metabolic diseases. The first NAMPT inhibitors (FK866 and CHS828) have already entered clinical trials, and a surge in interest in the synthesis of novel molecules has occurred. The present review summarizes the recent progress in this field.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679915     DOI: 10.1021/jm4001049

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  44 in total

1.  Treatment of Cancer with NAMPT Inhibitors.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-05-13       Impact factor: 4.345

2.  Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.

Authors:  Xin Yue Wang; Jin Zhi Wang; Lu Gao; Fu Yin Zhang; Qi Wang; Ke Jian Liu; Bin Xiang
Journal:  Toxicol Appl Pharmacol       Date:  2017-05-10       Impact factor: 4.219

3.  Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.

Authors:  Antonio F Santidrian; Sarah E LeBoeuf; Erik D Wold; Melissa Ritland; Jane S Forsyth; Brunhilde H Felding
Journal:  DNA Repair (Amst)       Date:  2014-09-26

4.  An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma.

Authors:  Amit D Gujar; Son Le; Diane D Mao; David Y A Dadey; Alice Turski; Yo Sasaki; Diane Aum; Jingqin Luo; Sonika Dahiya; Liya Yuan; Keith M Rich; Jeffrey Milbrandt; Dennis E Hallahan; Hiroko Yano; David D Tran; Albert H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-07       Impact factor: 11.205

5.  Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy.

Authors:  Nicolas Diguet; Samuel A J Trammell; Cynthia Tannous; Robin Deloux; Jérôme Piquereau; Nathalie Mougenot; Anne Gouge; Mélanie Gressette; Boris Manoury; Jocelyne Blanc; Marie Breton; Jean-François Decaux; Gareth G Lavery; István Baczkó; Joffrey Zoll; Anne Garnier; Zhenlin Li; Charles Brenner; Mathias Mericskay
Journal:  Circulation       Date:  2017-12-07       Impact factor: 29.690

6.  Crystal structure-based comparison of two NAMPT inhibitors.

Authors:  Sai-Long Zhang; Tian-Ying Xu; Zhen-Lin Yang; Shuo Han; Qiang Zhao; Chao-Yu Miao
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

7.  Scaffold Morphing Identifies 3-Pyridyl Azetidine Ureas as Inhibitors of Nicotinamide Phosphoribosyltransferase (NAMPT).

Authors:  Daniel S Palacios; Erik L Meredith; Toshio Kawanami; Christopher M Adams; Xin Chen; Veronique Darsigny; Mark Palermo; Daniel Baird; Elizabeth L George; Chantale Guy; Jeffrey Hewett; Laryssa Tierney; Sachin Thigale; Louis Wang; Wilhelm A Weihofen
Journal:  ACS Med Chem Lett       Date:  2019-10-10       Impact factor: 4.345

Review 8.  Physiological and pathophysiological roles of NAMPT and NAD metabolism.

Authors:  Antje Garten; Susanne Schuster; Melanie Penke; Theresa Gorski; Tommaso de Giorgis; Wieland Kiess
Journal:  Nat Rev Endocrinol       Date:  2015-07-28       Impact factor: 43.330

9.  NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.

Authors:  S M Hong; C W Park; S W Kim; Y J Nam; J H Yu; J H Shin; C H Yun; S-H Im; K-T Kim; Y C Sung; K Y Choi
Journal:  Oncogene       Date:  2015-11-16       Impact factor: 9.867

10.  Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Authors:  Michele Cea; Antonia Cagnetta; Chirag Acharya; Prakrati Acharya; Yu-Tzu Tai; Cao Yang; Davide Lovera; Debora Soncini; Maurizio Miglino; Giulio Fraternali-Orcioni; Luca Mastracci; Alessio Nencioni; Fabrizio Montecucco; Fiammetta Monacelli; Alberto Ballestrero; Teru Hideshima; Dharminder Chauhan; Marco Gobbi; Roberto M Lemoli; Nikhil Munshi; Steven P Treon; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2016-06-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.